Navigation Links
ARIUS announces second quarter fiscal 2008 financial results
Date:7/11/2008

TORONTO, July 11 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced its financial and operational results for the second fiscal quarter of 2008, ended May 31st, 2008.

"Throughout the second quarter, we maintained our focus on moving ARIUS' anti-cancer antibodies towards human clinical trial. Most notably, our lead drug candidates received significant attention from the scientific community this quarter as five abstracts were presented at the AACR Annual Meeting in April, disclosing new findings about our CD44, Trop-2, CD59, and CD9 antibody programs," said Dr. David Young, President and CEO of ARIUS. "Additionally, abstracts on our CD44 program were selected for publication at the ASCO Annual Meeting in May. The inclusion of ARIUS' findings at these important conferences demonstrates the high quality of our research and reinforces the value of our lead drug candidates."

Program Updates:

CD44 Cancer Stem Cell Program

- Presented two CD44-focused posters at AACR the American Association

for Cancer Research (AACR) Annual Meeting held from April 12-16, 2008

in San Diego, California.

- Published two CD44-focused abstracts at the American Association for

Clinical Oncology (ASCO) Annual Meeting held from May 30-June 3, 2008

in Chicago, Illinois.

- Held meeting with FDA to discuss plans for the upcoming IND

submission in the first quarter of 2008.

- ARIUS plans to have clinical trials' materials prepared in the fourth

quarter of 2008 and then a Phase I IND application is expected to be

filed and human clinical trials commenced.

Trop-2 Signal Transduction Program

- Completed two toxicology studies with no dose-limiting toxicity.

- Presented a Trop-2-focused poster at AACR Annual Meeting.

- Engaged
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ARIUS presents new findings for anti-cancer antibody programs at AACR
2. ARIUS announces first quarter fiscal 2008 financial results
3. ARIUS 2008 Annual and Special Meeting of Shareholders
4. ARIUS recognized for entrepreneurial excellence
5. ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting
6. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
7. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
8. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
9. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
10. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
11. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Israel , July 25, 2014  Galmed Pharmaceuticals ... biopharmaceutical company focused on the development and commercialization of ... diseases and cholesterol gallstones, today announced financial results for ... Half 2014 Financial Summary: , Reported cash and ... compared with $137,000 at December 31, 2013.  , ...
(Date:7/25/2014)... 2014 At the request of the ... 60-day extension for the public comment period (Docket No. ... Model Aircraft established by Congress as part of the ... extension establishes the new deadline for comments as September ... Transportation/FAA notice published in the Federal Register on July ...
(Date:7/24/2014)... New York, NY - July 24, 2014 -- Keryx ... results from the long-term, randomized, active control Phase 3 ... ferric iron-based phosphate binder, for the treatment of hyperphosphatemia ... The PERFECTED study (PhosphatE binding and iRon delivery with ... the Journal of the American Society of Nephrology ...
(Date:7/24/2014)... Calabasas, CA (PRWEB) July 24, 2014 ... advancing the Global Supply Chain of the biotech ... annual SCM Innovation Awards, brought to you by ... premiere global organization of supply chain management professionals ... be given to stakeholders of the Biotech industry ...
Breaking Biology Technology:Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6FAA Grants Comment Extension at the Request of AMA 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3
... , , DUBLIN, Ohio, ... to acquire the assets of privately held Biotech, an operator ... the Southwestern United States. , , Cardinal ... pharmacies and operates 26 cyclotron-based PET radiopharmaceutical manufacturing facilities. These ...
... ... for Jatropha Promotion & Biodiesel (CJP) a big breakthrough in the search for a viable ... of successful field trials, CJP is now happy to announce the much awaited commercial release ... ...
... ... Terrosa Technologies, a provider of Cloud and SaaS migration services ... sales, marketing and distribution responsibilities with Integrated Clinical Solutions for ... Trial Management System (CTMS) tool for the pharmaceutical clinical research ...
Cached Biology Technology:Cardinal Health Completes Biotech Acquisition 2Jatropha Couple Oil Crop Cultivation Technology Commercially Released 2Jatropha Couple Oil Crop Cultivation Technology Commercially Released 3Terrosa Technologies Assigned as Exclusive Reseller for Inclinicalperform CTMS/SaaS Clinical Trials Collaboration Software 2Terrosa Technologies Assigned as Exclusive Reseller for Inclinicalperform CTMS/SaaS Clinical Trials Collaboration Software 3
(Date:7/24/2014)... arose have been maintained in our cells today according to ... today in the Journal of Biological Chemistry reveals ... animals still perform ancient reactions thought to have been responsible ... ago. , The primordial soup theory suggests that life began ... combination of metals, gases from the atmosphere and some form ...
(Date:7/24/2014)... work with a new drug that successfully treated lupus in ... received a $250,000 grant to expand his research to a ... a wider range of autoimmune diseases., Chandra Mohan, Hugh Roy ... UH, previously published a study in Arthritis Research & Therapy ... lupus in mice and reduced the number of cases of ...
(Date:7/24/2014)... July 24, 2014 NXT-ID, Inc., (NXTD: OTCQB) a biometric ... its next generation smart wallet, Wocket™, was recently the topic of  ... interviewed Gino Pereira , CEO of NXT-ID, ... Mr. Gino Pereira explains ... of credit cards and walks host Anita Finley ...
Breaking Biology News(10 mins):Biomedical engineer looks at new applications for novel lupus drug 2Biomedical engineer looks at new applications for novel lupus drug 3Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 2Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 3Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 4
... turtles have been slow to give up the secrets ... For decades, paleontologists who study fossils and molecular biologists ... more closely related to birds and crocodiles or to ... Biological Laboratory in Bar Harbor, Maine, and their colleagues ...
... Bethesda, Md. (July 25, 2011)It,s no secret that ... a bevy of recent research suggests that these positive ... a new review article highlighting the results of more ... this topic, Michelle W. Voss, of the University of ...
... One of the latest attempts to boost the ... in which patients receive a therapeutic injection of their ... clinical trials for melanoma and neuroblastoma, has its limitations: ... outside the body for future re-injection is extremely expensive ...
Cached Biology News:Discovery places turtles next to lizards on family tree 2Exercise has numerous beneficial effects on brain health and cognition, review suggests 2Exercise has numerous beneficial effects on brain health and cognition, review suggests 3Universal donor immune cells 2
Mouse monoclonal [M7-PB-E9] to pan alpha Sodium Potassium ATPase ( Abpromise for all tested applications)....
Anti-Cohesin (Scc1/Rad21) Monoclonal Antibody Research Focus: signal transduction Storage: -20C Shipping Temperature: +4C...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
E2F2 protein...
Biology Products: